VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Molecular agents targeting the epidermal growth factor receptor (EGFR)‐, anaplastic lymphoma kinase (ALK)‐ or c‐ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significa...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Sci
Hoofdauteurs: Watanabe, Hiromi, Ichihara, Eiki, Kayatani, Hiroe, Makimoto, Go, Ninomiya, Kiichiro, Nishii, Kazuya, Higo, Hisao, Ando, Chihiro, Okawa, Sachi, Nakasuka, Takamasa, Kano, Hirohisa, Hara, Naofumi, Hirabae, Atsuko, Kato, Yuka, Ninomiya, Takashi, Kubo, Toshio, Rai, Kammei, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2021
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088971/
https://ncbi.nlm.nih.gov/pubmed/33410241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14801
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items